395 related articles for article (PubMed ID: 6418407)
1. Clinical efficacy and electrophysiologic effects of encainide in patients with Wolff-Parkinson-White syndrome.
Prystowsky EN; Klein GJ; Rinkenberger RL; Heger JJ; Naccarelli GV; Zipes DP
Circulation; 1984 Feb; 69(2):278-87. PubMed ID: 6418407
[TBL] [Abstract][Full Text] [Related]
2. Encainide for treatment of atrioventricular reciprocating tachycardia in the Wolff-Parkinson-White syndrome.
Miles WM; Zipes DP; Rinkenberger RL; Markel ML; Prystowsky EN; Dougherty AH; Heger JJ; Naccarelli GV
Am J Cardiol; 1988 Dec; 62(19):20L-25L. PubMed ID: 3144163
[TBL] [Abstract][Full Text] [Related]
3. Electrophysiologic and clinical effects of intravenous and oral encainide in accessory atrioventricular pathway.
Kunze KP; Kuck KH; Schlüter M; Kuch B; Bleifeld W
Am J Cardiol; 1984 Aug; 54(3):323-9. PubMed ID: 6431796
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and electrophysiologic effects of intravenous and oral encainide in patients with accessory atrioventricular pathways and supraventricular arrhythmias.
Abdollah H; Brugada P; Green M; Wehr M; Wellens HJ
Am J Cardiol; 1984 Sep; 54(6):544-9. PubMed ID: 6433688
[TBL] [Abstract][Full Text] [Related]
5. Encainide for atrial fibrillation associated with Wolff-Parkinson-White syndrome.
Rinkenberger RL; Naccarelli GV; Miles WM; Markel ML; Dougherty AH; Prystowsky EN; Heger JJ; Zipes DP
Am J Cardiol; 1988 Dec; 62(19):26L-30L. PubMed ID: 3144164
[TBL] [Abstract][Full Text] [Related]
6. Encainide for treatment of supraventricular tachycardias associated with the Wolff-Parkinson-White syndrome.
Markel ML; Prystowsky EN; Heger JJ; Miles WM; Fineberg N; Zipes DP
Am J Cardiol; 1986 Aug; 58(5):41C-48C. PubMed ID: 3092619
[TBL] [Abstract][Full Text] [Related]
7. Electrophysiology of oral encainide.
Jackman WM; Zipes DP; Naccarelli GV; Rinkenberger RL; Heger JJ; Prystowsky EN
Am J Cardiol; 1982 Apr; 49(5):1270-8. PubMed ID: 6801954
[TBL] [Abstract][Full Text] [Related]
8. [Electrophysiologic properties of cibenzoline in Wolff-Parkinson-White syndrome and atrioventricular nodal reentry tachycardia].
Kühlkamp V; Ickrath O; Schmid F; Mayer F; Haasis R; Seipel L
Z Kardiol; 1989 Oct; 78(10):640-6. PubMed ID: 2686251
[TBL] [Abstract][Full Text] [Related]
9. Electrophysiologic and clinical effects of intravenous and oral encainide in patients with Wolff-Parkinson-White syndrome and paroxysmal atrial fibrillation.
Chimienti M; Moizi M; Salerno JA; Klersy C; Guasti L; Previtali M; Marangoni E; Montemartini C; Bobba P
Eur Heart J; 1987 Mar; 8(3):282-90. PubMed ID: 3107987
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal clinical and electrophysiological assessment of patients with symptomatic Wolff-Parkinson-White syndrome and atrioventricular node reentrant tachycardia.
Chen SA; Chiang CE; Tai CT; Lee SH; Chiou CW; Ueng KC; Wen ZC; Cheng CC; Chang MS
Circulation; 1996 Jun; 93(11):2023-32. PubMed ID: 8640978
[TBL] [Abstract][Full Text] [Related]
11. Electrophysiologic and clinical effects of oral encainide in paroxysmal atrioventricular node reentrant tachycardia.
Chimienti M; Li Bergolis M; Moizi M; Salerno JA
J Am Coll Cardiol; 1989 Oct; 14(4):992-8. PubMed ID: 2507613
[TBL] [Abstract][Full Text] [Related]
12. Transesophageal versus intracardiac atrial stimulation in assessing anterograde conduction properties of the accessory pathway in Wolff-Parkinson-White syndrome.
Favale S; Minafra F; Massari V; Tritto M; Rizzon P
Int J Cardiol; 1991 Feb; 30(2):209-14. PubMed ID: 2010244
[TBL] [Abstract][Full Text] [Related]
13. Effect of propafenone in the Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up.
Breithardt G; Borggrefe M; Wiebringhaus E; Seipel L
Am J Cardiol; 1984 Nov; 54(9):29D-39D. PubMed ID: 6496367
[TBL] [Abstract][Full Text] [Related]
14. Suppression of incessant supraventricular tachycardia by intravenous and oral encainide.
Brugada P; Abdollah H; Wellens HJ
J Am Coll Cardiol; 1984 Dec; 4(6):1255-60. PubMed ID: 6438205
[TBL] [Abstract][Full Text] [Related]
15. Concealed conduction in accessory atrioventricular pathways: an important determinant of the expression of arrhythmias in patients with Wolff-Parkinson-White syndrome.
Klein GJ; Yee R; Sharma AD
Circulation; 1984 Sep; 70(3):402-11. PubMed ID: 6744543
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and electrophysiologic effects of encainide for atrioventricular nodal reentrant tachycardia.
Naccarelli GV; Jackman WM; Akhtar M; Rinkenberger RL; Friday KJ; Dougherty AH; Tchou P; Yeung-Lai-Wah JA
Am J Cardiol; 1988 Dec; 62(19):31L-36L. PubMed ID: 3144165
[TBL] [Abstract][Full Text] [Related]
17. Propofol has no direct effect on sinoatrial node function or on normal atrioventricular and accessory pathway conduction in Wolff-Parkinson-White syndrome during alfentanil/midazolam anesthesia.
Sharpe MD; Dobkowski WB; Murkin JM; Klein G; Yee R
Anesthesiology; 1995 Apr; 82(4):888-95. PubMed ID: 7717560
[TBL] [Abstract][Full Text] [Related]
18. Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation.
Roden DM; Lee JT; Woosley RL; Echt DS
Circulation; 1989 Nov; 80(5):1247-58. PubMed ID: 2805262
[TBL] [Abstract][Full Text] [Related]
19. Effect of atropine and isoproterenol on tachycardia induction in asymptomatic patients with Wolff-Parkinson-White electrocardiographic pattern.
Kim YH; Leitch JW; Klein GJ; Yee R; Leather RA
Can J Cardiol; 1992 Sep; 8(7):716-20. PubMed ID: 1422992
[TBL] [Abstract][Full Text] [Related]
20. Electrophysiologic effects of oral propafenone in Wolff-Parkinson-White syndrome studied by programmed electrical stimulation.
Sethi KK; Prasad GS; Mohan JC; Arora R; Khalilullah M
Indian Heart J; 1991; 43(1):5-10. PubMed ID: 1894303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
